Global Information
회사소개 | 문의 | 위시리스트

약제 분석 : 바벤시오(Bavencio)

Bavencio

리서치사 Datamonitor Healthcare
발행일 2019년 03월 상품 코드 603909
페이지 정보 영문 86 Pages
가격
US $ 10,000 ₩ 11,808,000 PDF by E-mail (Single User License)


약제 분석 : 바벤시오(Bavencio) Bavencio
발행일 : 2019년 03월 페이지 정보 : 영문 86 Pages

PD-L1 단백질을 표적으로 한 완전 인간형 모노클로널 항체(MAb), Bavencio(바벤시오)에 대해 조사했으며, 주요 국가/지역의 매출 실적과 예측, 질환별 약제 평가·SWOT 분석 및 약제 개요 등을 정리하여 전해드립니다.

  • 제품 개요
  • 개요
  • Bavencio(바벤시오) : 두경부암
  • Bavencio(바벤시오) : 난소암
  • Bavencio(바벤시오) : 방광암
  • avelumab(아벨루맙) : 신세포암(RCC)
  • avelumab : 비소세포폐암(NSCLC)
  • avelumab : 위암
KSA 18.02.23

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
    • Bavencio: Renal cell carcinoma (RCC)
    • Bavencio: NHL: Diffuse large B-cell lymphoma (DLBCL)
    • Bavencio: Non-small cell lung cancer (NSCLC)
    • Bavencio: Gastric cancer
    • Bavencio: Head and neck cancer
    • Bavencio: Ovarian cancer
    • Bavencio: Bladder cancer

LIST OF FIGURES

  • Figure 1: Bavencio for RCC - SWOT analysis
  • Figure 2: Datamonitor Healthcare's drug assessment summary of Bavencio for RCC
  • Figure 3: Datamonitor Healthcare's drug assessment summary of Bavencio for RCC
  • Figure 4: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 5: Bavencio for diffuse large B-cell lymphoma - SWOT analysis
  • Figure 6: Datamonitor Healthcare's drug assessment summary for Bavencio in diffuse large B-cell lymphoma
  • Figure 7: Datamonitor Healthcare's drug assessment summary for Bavencio in diffuse large B-cell lymphoma
  • Figure 8: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 9: Bavencio for non-small cell lung cancer - SWOT analysis
  • Figure 10: Datamonitor Healthcare's drug assessment summary for Bavencio in non-small cell lung cancer
  • Figure 11: Datamonitor Healthcare's drug assessment summary for Bavencio in non-small cell lung cancer
  • Figure 12: Bavencio sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 13: Bavencio for gastric cancer - SWOT analysis
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 15: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 16: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 17: Bavencio for head and neck cancer - SWOT analysis
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Bavencio for SCCHN
  • Figure 20: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 21: Bavencio for ovarian cancer - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment of Bavencio for ovarian cancer
  • Figure 23: Datamonitor Healthcare's drug assessment of Bavencio for ovarian cancer
  • Figure 24: Bavencio for urothelial bladder cancer - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Bavencio in urothelial bladder cancer

LIST OF TABLES

  • Table 1: Bavencio drug profile
  • Table 2: Bavencio Phase III data in RCC
  • Table 3: Bavencio sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 4: Bavencio drug profile
  • Table 5: Bavencio ongoing pivotal trial in diffuse large B-cell lymphoma
  • Table 6: Bavencio sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 7: Bavencio drug profile
  • Table 8: Bavencio Phase III trials in non-small cell lung cancer
  • Table 9: Bavencio Phase III trial data in non-small cell lung cancer
  • Table 10: Bavencio early-phase data in non-small cell lung cancer
  • Table 11: Bavencio sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 12: Bavencio patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 13: Bavencio drug profile
  • Table 14: Bavencio Phase III trials in gastric cancer
  • Table 15: Bavencio Phase III trial data in gastric cancer
  • Table 16: Bavencio early-phase data in gastric cancer
  • Table 17: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 18: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 19: Bavencio drug profile
  • Table 20: Bavencio Phase III trials in head and neck cancer
  • Table 21: Bavencio early-phase data in head and neck cancer
  • Table 22: Bavencio sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 23: Bavencio patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 24: Bavencio drug profile
  • Table 25: Bavencio Phase III trials in ovarian cancer
  • Table 26: Overview of Phase I data for Bavencio in ovarian cancer
  • Table 27: Bavencio drug profile
  • Table 28: Bavencio pivotal trial data in urothelial bladder cancer
  • Table 29: Bavencio ongoing late-phase trials in urothelial bladder cancer
Back to Top
전화 문의
F A Q